188 related articles for article (PubMed ID: 31189528)
1. B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency.
Oshrine B; Grana N; Moore C; Nguyen J; Crenshaw M; Edwards M; Sudhaman S; Forster VJ; Tabori U
Blood Adv; 2019 Jun; 3(12):1795-1798. PubMed ID: 31189528
[TBL] [Abstract][Full Text] [Related]
2. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Cassaday RD; Marks DI; DeAngelo DJ; Jabbour EJ; Advani AS; O'Brien S; Wang T; Neuhof A; Vandendries E; Kantarjian HM; Stock W; Stelljes M
Br J Haematol; 2020 Nov; 191(3):e77-e81. PubMed ID: 32805058
[No Abstract] [Full Text] [Related]
3. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
4. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
6. Inotuzumab ozogamicin in acute lymphoblastic leukaemia.
Gourd E
Lancet Oncol; 2019 May; 20(5):e248. PubMed ID: 30956118
[No Abstract] [Full Text] [Related]
7. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
Calvo C; Cabannes-Hamy A; Adjaoud D; Bruno B; Blanc L; Boissel N; Tabone MD; Willson-Plat G; Villemonteix J; Baruchel A; Brethon B
Br J Haematol; 2020 Jul; 190(1):e53-e56. PubMed ID: 32424837
[No Abstract] [Full Text] [Related]
8. Metachronous T-Lymphoblastic Lymphoma and Burkitt Lymphoma in a Child With Constitutional Mismatch Repair Deficiency Syndrome.
Alexander TB; McGee RB; Kaye EC; McCarville MB; Choi JK; Cavender CP; Nichols KE; Sandlund JT
Pediatr Blood Cancer; 2016 Aug; 63(8):1454-6. PubMed ID: 27037742
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
10. Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency.
Larouche V; Atkinson J; Albrecht S; Laframboise R; Jabado N; Tabori U; Bouffet E;
Pediatr Blood Cancer; 2018 Dec; 65(12):e27389. PubMed ID: 30160041
[No Abstract] [Full Text] [Related]
11. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
DeAngelo DJ; Advani AS; Marks DI; Stelljes M; Liedtke M; Stock W; Gökbuget N; Jabbour E; Merchant A; Wang T; Vandendries E; Neuhof A; Kantarjian H; O'Brien S
Blood Cancer J; 2020 Aug; 10(8):81. PubMed ID: 32769965
[TBL] [Abstract][Full Text] [Related]
12. Metachronous Wilms Tumor, Glioblastoma, and T-cell Leukemia in an Child With Constitutional Mismatch Repair Deficiency syndrome due to Novel Mutation in MSH6 (c.2590G>T).
Citak EC; Sagcan F; Gundugan BD; Bozdogan ST; Yilmaz EB; Avci E; Balci Y; Karabulut YY
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e198-e202. PubMed ID: 31815888
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
14. Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.
Kantarjian HM
Clin Adv Hematol Oncol; 2019 May; 17(5):268-270. PubMed ID: 31188803
[No Abstract] [Full Text] [Related]
15. Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.
Gallon R; Phelps R; Betts L; Hayes C; Masic D; Irving JAE; McAnulty C; Saha V; Vora A; Wimmer K; Motwani J; Macartney C; Burn J; Jackson MS; Moorman AV; Santibanez-Koref M
Leuk Lymphoma; 2023 Jan; 64(1):217-220. PubMed ID: 36272172
[No Abstract] [Full Text] [Related]
16. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome.
Ripperger T; Schlegelberger B
Eur J Med Genet; 2016 Mar; 59(3):133-42. PubMed ID: 26743104
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in frontline acute lymphoblastic leukemia.
Chew S; Jammal N; Kantarjian H; Jabbour E
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101226. PubMed ID: 33279178
[TBL] [Abstract][Full Text] [Related]
18. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
19. Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome.
Galuppini F; Opocher E; Tabori U; Mammi I; Edwards M; Campbell B; Kelly J; Viel A; Quaia M; Rivieri F; D'Avella D; Arcella A; Giangaspero F; Fassan M; Gardiman MP
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):233-239. PubMed ID: 29130549
[No Abstract] [Full Text] [Related]
20. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
Marks DI; van Oostrum I; Mueller S; Welch V; Vandendries E; Loberiza FR; Böhme S; Su Y; Stelljes M; Kantarjian HM
Cancer Med; 2019 Oct; 8(13):5959-5968. PubMed ID: 31436395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]